Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin.

Schrott1, Fereshetian, Knopp

  • 1The Lipid Center, University of Iowa, Iowa City, Iowa, USA

Journal of Cardiovascular Pharmacology and Therapeutics
|February 23, 2000
PubMed
Summary

Atorvastatin effectively reduces LDL cholesterol and triglycerides in patients with high cholesterol. This study found atorvastatin calcium to be safe and well-tolerated across various doses over six weeks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teeth of Old Age.

The American journal of dental science·2019
Same author

Ulcerated Legs : Their Care and Cure.

The Hospital·2018
Same author

Observations on the Topical Pathology of the Neuralgiæ.

Provincial medical journal and retrospect of the medical sciences·2011
Same author

A lament for art in/of medicine.

Journal of primary health care·2010
Same author

DISCUSSION ON THE TREATMENT BY PHYSICAL METHODS OF MEDICAL DISABILITIES INDUCED BY THE WAR.

Proceedings of the Royal Society of Medicine·2009
Same author

Fatty acid compositions of gonadal material and diets of the sea urchin, Psammechinus miliaris: trophic and nutritional implications.

Journal of experimental marine biology and ecology·2000

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Coronary heart disease (CHD) is a leading cause of death.
  • Elevated low-density lipoprotein (LDL) cholesterol and triglycerides (TG) are significant risk factors for CHD.
  • 3-Hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors are effective in managing hypercholesterolemia.

Purpose of the Study:

  • To evaluate the safety and dose-response effects of atorvastatin calcium.
  • To assess atorvastatin's impact on lipoprotein fractions in patients with specific LDL cholesterol and TG levels.

Main Methods:

  • A 6-week, randomized, placebo-controlled, parallel-group study.
  • Sixty-five patients received placebo or atorvastatin (10, 20, 40, 60, or 80 mg) daily.
  • Lipoprotein levels and adverse events were monitored.

Related Experiment Videos

Main Results:

  • Atorvastatin significantly decreased LDL cholesterol in a dose-dependent manner (37%–59%) compared to placebo (P =.0001).
  • Significant reductions in total cholesterol, triglycerides, and apolipoprotein B were observed across atorvastatin groups (P =.0001).
  • Adverse events were comparable between atorvastatin and placebo groups, with no serious events or withdrawals due to adverse events.

Conclusions:

  • Atorvastatin demonstrates effective dose-related reductions in plasma LDL cholesterol, triglycerides, and apolipoprotein B.
  • The study confirms atorvastatin's good tolerability in hyperlipidemic patients over a 6-week treatment period.